113 results about "Prothoracic gland" patented technology

Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid—polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.

The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

The invention provides a kit for detecting human immune ages and an application of the kit. Reagents in the kit comprise CD3, CD4, CD31 and CD45RA monoclonal antibodies which are four fluoresceins applicable to flow cytometers, and the colors of the four fluoresceins are different. The reagents in the kit comprise, in weight percent, 0.66-94.34% of fluorescent labeled CD3, 0.66-94.34% of fluorescent labeled CD4, 0.66-94.34% of fluorescent labeled CD31 and 0.66-94.34% of fluorescent labeled CD345RA. The kit is used for detecting recently outputted cell number of human thymuses, the immune agesof people are determined according to detection results of the recently outputted cell number of the human thymuses, and the immune ability of a human body is evaluated.

The invention discloses a medical composition for facilitating repair of hematopoietic damage. The medical composition comprises recombinant human bone morphogenetic protein-2 and human granulocyte stimulating factors, through the favorable synergistic reaction of the recombinant human bone morphogenetic protein-2 and the human granulocyte stimulating factors, recovery of hematopoietic stem cells, functional cells of a spleen and functional cells of a thymus during the hematopoietic damage can be effectively facilitated, the recovery of blood cells of peripheral blood when a hematopoietic function is poor can also be facilitated, the recovery of white blood cells of the peripheral blood during bone marrow transplantation can be accelerated, and the medical composition can be used as a medicine for preventing and / or treating the hematopoietic damage and a mobilizing agent for transplantation of stem cells of the peripheral blood.

The invention discloses a swine fever oral attenuated freezing-dry vaccine and a preparation method thereof and a freeze-drying protective agent, the swine fever oral attenuated freezing-dry vaccine includes antigen swine fever virus, a mucosal adjuvant and the freeze-drying protective agent, the freeze-drying protective agent includes 1-3% of gelatin, 1-3% of glycine and balance of water, the swine fever oral attenuated freezing-dry vaccine can well protect the activity of CSFV (Classical Swine Fever Virus), reduces live virus loss, can induce higher levels of IgG and IgA antibodies in oral immunization tests of mice, can promote expression of type I interferon in thymus and spleen, has the effect of protecting antigen activity and improving oral swine fever antigen immune efficiency, and can be used as a swine fever oral vaccine protective agent for industry development.

An object of the present invention is to produce a mammalian organ having a complicated cellular composition composed of multiple kinds of cells, such as kidney, pancreas, thymus and hair, in the living body of a non-human animal. The inventors of the present invention applied the chimeric animal assay described above, to a novel solid organ production method. More specifically, the inventors has shown that a model mouse which is deficient of kidney, pancreas, thymus or hair due to the dysfunction of the metanephric mesenchyme that is differentiated into most of an adult kidney, is rescued by blastocyst complementation by the chimeric animal assay, and whereby a kidney, a pancreas, thymus or hair can be newly produced.

A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism.

Pomegranate juice consumption by a patient may be used to treat prostate cancer. Prior to the present invention, it has been observed that various pomegranate compositions have cancer chemopreventive properties on various in vitro treatment of human prostate cancer cell lines and in vivo treatment of human prostate cancer cell lines xenografted in athymic nude mice. Until the discovery of the present invention, it was not known if there is an efficacy for treating prostate cancer in human patient by any route of administration. The present invention provides a method of treating a subject with prostate cancer a composition comprising a therapeutically effective amount of an extract from pomegranate fruit. The extract of pomegranate may be a juice extract of pomegranate, an extract from inner or outer peel of pomegranate, or mixture thereof. Pomegranate juice may be used to treat subjects with rising serum PSA after prostate surgery or radiotherapy.

A kind of inartificial medicine Rabdosia.serra (Maxim) Hara extraction materials which may cure hepatitis and its preparation method is disclosed in the invention, which acts Rabdosia.serra (Maxim) Hara as materials, adopts one of the hot water, supercriticality CO2 or organic impregnant extracting methods, and executes Rabdosia.serra (Maxim) Hara extracting materials by decompression condensation, vacuum dryness, spray dryness etc. methods. It contains antivirus active component 2-hydroxyl ursocic acid, 2,3-di hydroxyl ursocic acid and antioxygenation active component rosmarinic acid and so on speciality valid components, and so it has restraining HBV copy, protecting immunity liver damnification, advancing cell immunity and increasing spleen, thymus weight, bile drainage of low immunity experiment animals etc. functions.

The invention discloses a new purpose of a compound Chinese Lobelia formulation for treating tumor or treating tumor in conjunction with chemotherapeutic treatment and radiation treatment, which belongs to the field of traditional Chinese medicine. Aiming at various injuries such as universal and serious damage to immunity of the organism, obvious reduction of white blood cells, bacterial infection, pain, and the like caused by simulative chemotherapeutic treatment and radiation treatment to a patient who suffers from tumor, experimental results indicate that the compound Chinese Lobelia formulation can obviously enhance the immunologic function, can remarkably increase the phagocytic function of scavenger cells, has protective action for reducing white blood cells, and has the weighting function for spleen and thymus; the compound Chinese Lobelia formulation has a certain in-vitro antibacterial action for staphylococcus aureus (G+) and colon bacillus (G-), has obvious protective function for a mouse infected by staphylococcus aureus and colon bacillus, can obviously reduce the death rate of the infected mouse and delay the death time to some extent; and the compound Chinese Lobelia formulation has obvious analgestic action for rats and mousse. The experimental results explain that the compound Chinese Lobelia formulation can be used for treating tumor or used for treating tumor in conjunction with chemotherapeutic treatment and radiation treatment and can increase the tolerance and the adaptability of a patient for chemotherapeutic treatment, strengthen the immunity of an organism, shorten the period of chemotherapeutic treatment or radiation treatment, reduce the toxic side reaction in chemotherapeutic treatment or radiation treatment, lower the death rate of a tumor patient and improve the life quality of a patient.

The present invention relates generally to the fields of pharmacology, and particularly to a method for treating inflammation, particularly inflammation of the respiratory system. The invention provides a method to reduce or ameliorate inflammation, by administering an effective amount of a protein factor originally isolated from thymic tissue, and referred to as T4 immune stimulating factor (TISF).

The invention discloses a peptide-containing milk and process for preparation. The milk of the invention is processed through charging thymus polypeptide extract extracted from fetal bovine thymus tissue into common milk, and then processing through homogeneous process. During preparing the thymus polypeptide extract, steps of homogenate, freezing and thawing, interception, filtering and the like are employed, thereby processing thymus polypeptide extract with molecular weight < 30000 Daltons. A lot of experiments prove that the peptide-containing milk of the invention has the functions of enhancing immunity and stimulating stem cells to proliferate.

The invention discloses a flow cytometry detection method for mouse thymus or spleen T-lymphocyte subsets. The method comprises the following steps: acquiring thymus or spleen tissues of tested mice, and preparing single-cell suspension; respectively sucking the single-cell suspension of the thymus or spleen, respectively adding anti-mouse DC3, CD4 and CD8 monoclonal antibodies, swirling and uniformly mixing, keeping away from light at the temperature of 4 DEG C and staining; washing with PBS (Phosphate Buffer Solution) after staining, resuspending the cells, and detecting by using flow cytometry; and analyzing the detection result, thereby obtaining the percentage of each T-lymphocyte subset of the thymus or spleen of the mice. The stable and standardized method for detecting the mouse thymus or spleen T-lymphocyte subsets through flow cytometry is successfully established in the invention. By improving the problems such as target cell selection, compensative regulation and parameter selection in the sample pretreatment, detection and analysis process, errors caused by human factors in the test process are avoided, and the authenticity and objectivity of result judgment are improved.

A method for expressing the thymopeptide alpha 1 by yeast includes such steps as using PCR technique to amplify the whole-length gene of thymopeptide alpha 1, enzyme severing at both ends, and cloning it to yeast while stably expressing it in yeast. The expressed thymopeptide alpha 1 with very high bioactivity can be used to treat tumor, viral and immunodeficiency diseases, and hypothymism, or used as vaccine intensifier.

The present disclosure provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

An application of doxycycline in promoting the reproduction of cells, such as the cells MTEC1, TEC1C8, TNC-R3.1, HEK293, CTX-3, etc, is disclosed.

The invention discloses a traditional Chinese medicine feed supplement and an application thereof. The traditional Chinese medicine feed supplement, which is livestock and poultry feed supplement, comprises the following traditional Chinese medicine raw materials by mass part: 10-60 parts of blueberry, 10-60 parts of Indian buead, 10-60 parts of marine algae, 10-60 parts of honeysuckle and 310-60 parts of oyster. The livestock and poultry feed supplement can reduce the egg cholesterol level, improve the content of selenium, iron and zinc of the egg, as well as the DHA content of the egg and weight of spleen and bursa of fabricius, enhance the relative number of T and B lymphocyte in tonsillas in the thymus, spleen, bursa of fabricius and caecal, and improve the T lymphocyte conversion rate of blood serum of the egg.

The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections / AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.

A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 5% of recovered oils, and which may be distilled from the plant.

The invention discloses application of a scirpusin component C in common burreed rhizome in synthesis of anti-blood stasis syndrome drugs. The invention first proves that the scirpusin C has an obvious anti-blood stasis drug effect, and can be used for preparing a medicine for treating the blood stasis syndrome. Pharmacological experiments prove that the scirpusin C is capable of obviously reducing the levels of thromboxane B2 (TXB2), fibrinogen (FIB), active plasminogen activator inhibitor (PAI-1) and endothelin 1 (ET-1) in serum of blood stasis model mice and improving the thymus index (TI),spleen index (SI) and hepatic index (HI) of the mice, and has high clinical application value and development prospects in the aspect of treating the blood stasis syndrome.

The invention discloses a polypeptide chest enlargement essence cosmetic and a preparation method thereof. The cosmetic is rich in beauty polypeptide components and mainly comprises acetyl hexapeptide-38, growth-modulating peptide GHK, palmitoyl-pentapeptide-3, palmitoyl-oligopeptide, acetyl dipeptide-13, 2% carbomer 940, aloe extract, xanthan gum, glycerin, butanediol, hyaluronic acid, methylparaben, germall and water. The essence contains abundant active polypeptide components and supplements nutrients required by thymocyte, cell proliferation is promoted from different ways, and accordinglythe good chest enlargement effect is achieved. The cosmetic is good in safety, has no toxic or side effect and can be used for a long time.

The present invention belongs to the field of molecular biology and biological technology. From thymus tissue of milk cow, the milk cow prothoracic gland hormone coding gene is separated. Specific primer pair for inverse transcription and PCR proliferation is designed, and the milk cow prothoracic gland hormone coding gene separated via inverse transcription and PCR has sequence length of 330 bases. The expression vector is further constituted for transforming host cell to obtain prothoracic gland hormone protein with high activity from the host cell culture liquid. The recombinant gene of the present invention may be used in the industrial production of thymosin as one medicine product.

The invention provides a pharmaceutical composition for treating diarrhea and a preparation method and use thereof. Specifically, the pharmaceutical composition is prepared from the following raw materials in weight proportion: 400-600 parts of Atractylodes macrocephala Koidz and 400-600 parts of ginseng. The experimental results show that the pharmaceutical composition of the invention can remarkably increase the body weight, thymus and spleen index of 5-FU chemotherapy mice inhibited the pathological changes of ileocolon and alleviated diarrhea.

The aim of the present invention is to provide a method of acquiring immunological tolerance to a foreign DNA or its expression product whereby the foreign DNA such as a vector carrying a foreign gene incorporated thereinto or its expression product can be recognized not as non-self but as self; a method of sustaining a gene therapeutic effect whereby a rejection to a foreign DNA such as a vector carrying a foreign gene incorporated thereinto or its expression product can be avoided; and a non-human animal which has acquired immunological tolerance to a foreign DNA such as a vector carrying a foreign gene incorporated thereinto or its expression product. Fetal immature T lymphocytes transferred with a foreign DNA, such as a foreign gene-incorporated viral vector, are introduced into thymus and said foreign DNA is expressed in the thymus organ. The methods of transferring said foreign DNA into a fetal immature T lymphocyte include, for example, co-cultivating the fetal immature T lymphocytes with viral vector-infected virus producer cells.

The invention discloses new application of protocatechuic acid in the aspect of immune function promotion of livestock, especially in the aspects of peripheral blood CD4+ / CD8+T cell dynamic balance maintenance of livestock, cytokine secreting adjustment and the like. Influences of protocatechuic acid on the immune function, especially on T cell differentiation, of livestock are evaluated, 20 mg of protocatechuic acid is applied to each kilogram of body weight, protocatechuic acid is continuously taken orally for seven days, and results show that protocatechuic acid can effectively increase the peripheral blood CD4+ / CD8+T ratio, promote cytokine secreting in thymuses and the spleen and selectively adjust related genes of the immune system. The invention further provides a livestock immune promoter containing an effective dose of protocatechuic acid. Medical auxiliary materials can be added and prepared into various preparations, such as powder, tablets, granules and oral liquid, according to a conventional preparation method in the field. The effective dose is 5-40 mg for each kilogram of body weight, and the preparation is taken in a mixing mode or with water.